- Home
- CISS vs ENVB Comparison
CISS vs ENVB Comparison
Compare CISS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- ENVB
- Stock Information
- Founded
- CISS 2022
- ENVB 1994
- Country
- CISS Greece
- ENVB United States
- Employees
- CISS N/A
- ENVB N/A
- Industry
- CISS Marine Transportation
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- ENVB Health Care
- Exchange
- CISS Nasdaq
- ENVB Nasdaq
- Market Cap
- CISS 2.8M
- ENVB 3.1M
- IPO Year
- CISS N/A
- ENVB N/A
- Fundamental
- Price
- CISS $3.35
- ENVB $1.32
- Analyst Decision
- CISS
- ENVB Strong Buy
- Analyst Count
- CISS 0
- ENVB 1
- Target Price
- CISS N/A
- ENVB $10.00
- AVG Volume (30 Days)
- CISS 125.1K
- ENVB 107.1K
- Earning Date
- CISS 08-21-2025
- ENVB 08-11-2025
- Dividend Yield
- CISS N/A
- ENVB N/A
- EPS Growth
- CISS N/A
- ENVB N/A
- EPS
- CISS N/A
- ENVB N/A
- Revenue
- CISS $38,174,754.00
- ENVB N/A
- Revenue This Year
- CISS N/A
- ENVB N/A
- Revenue Next Year
- CISS N/A
- ENVB N/A
- P/E Ratio
- CISS N/A
- ENVB N/A
- Revenue Growth
- CISS N/A
- ENVB N/A
- 52 Week Low
- CISS $2.85
- ENVB $1.01
- 52 Week High
- CISS $23.25
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- CISS 44.02
- ENVB 57.52
- Support Level
- CISS $3.26
- ENVB $1.19
- Resistance Level
- CISS $3.49
- ENVB $1.28
- Average True Range (ATR)
- CISS 0.23
- ENVB 0.06
- MACD
- CISS -0.00
- ENVB 0.02
- Stochastic Oscillator
- CISS 28.72
- ENVB 91.48
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.